chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The patient woke up on 03/22/21 at 7:30 with multiple symptoms.  He had a fever of 100.5, both hands were swollen to the point he couldn't make a fist, a rash from wrist to elbow on right arm, chills and overall hurting from head to toes.  By the evening he had a rash on both legs from ankles to hips.  He lost his appetite for two days.  Also, for two days his glucose levels were between 300 and 408.  Patient took acetaminophen but it didn't relieve his fever.  His wife called his primary care provider, on 03/22/21.  She was instructed to call a hot-line, which ended up being our county health department.  She was told by them to contact his primary health provider.  She didn't call the primary provider again.  The patient's symptoms had resolved by 03/25/22 except for the rash on his right arm.  The wife called Care physician on 04/09/2021 to talk abouth what happened to her husband.  This time provider called the state hot-line.  The state hot-line advised the patient not to take the second shot because the symptoms could be worse or fatal.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose number unknow, single for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications.Other medication in 2weeks. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 included: Anti-viral details: Product: COVID 19 Treatment, Brand: Paxlovid, from 15Oct2022 to 19Oct2022 for treatment of COVID-19.
swelling arm; warm on injection site; lost appetite; red spot on injection site; chills; felt tired; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PERIPHERAL SWELLING (swelling arm), INJECTION SITE WARMTH (warm on injection site), DECREASED APPETITE (lost appetite), INJECTION SITE ERYTHEMA (red spot on injection site) and CHILLS (chills) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 003B21A. and 011A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included AMLODIPINE BESILATE (NORVASC) for an unknown indication.   On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Mar-2021, the patient experienced PERIPHERAL SWELLING (swelling arm), INJECTION SITE WARMTH (warm on injection site), DECREASED APPETITE (lost appetite), INJECTION SITE ERYTHEMA (red spot on injection site), CHILLS (chills) and FATIGUE (felt tired). The patient was treated with ASPIRIN [ACETYLSALICYLIC ACID] for Adverse event, at a dose of UNK dosage form. At the time of the report, PERIPHERAL SWELLING (swelling arm), INJECTION SITE WARMTH (warm on injection site), DECREASED APPETITE (lost appetite), INJECTION SITE ERYTHEMA (red spot on injection site), CHILLS (chills) and FATIGUE (felt tired) outcome was unknown. Not Provided
Felt as though hips and elbows were dislocating- extreme pain that caused emotional upset for the day as well as pain throughout joints for several days.
sleeping for 20 hours for four days after vaccine, low grade fever, chills, intense pain in right hip and left leg -intensification of arthritis pain, inability to walk on own, swollen left ankle due to inflammation, glucosed level increased for 1 1/2 weeks levels 171 to 261, brain fog , unable to do puzzles (puzzles helps with dementia.  Symptoms subsided after 2 weeks and 1 day; brain fog still subsiding, almost back to level before vaccination.
Started having symptoms of CFIDS again within a few weeks of the vaccine leading to having to quit my job. Then had a heart attack a month and a half later.
Father took covid vaccine. 1 week later, he had a stroke; This is a spontaneous report from a contactable consumer via the Pfizer-sponsored program. A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as a single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. It was reported that the patient took the covid vaccine and 1 week later (unspecified date), he had a stroke. The event stroke was assessed as serious (medically significant). The outcome of the event was unknown.  Information about lot/batch has been requested.
When dilution was performed.  1.9 ml of NaCl was used instead of 1.8ml.
Rash all over body; very itchy; This is a spontaneous report from a non-contactable consumer (patient herself). A 73-years-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 24Feb2021 (age at vaccination: 73 years) as DOSE NUMBER UNKNOWN, SINGLE for covid-19 immunisation. The patient medical history was not reported. Concomitant medication(s) included hydrochlorothiazide 25mg; rosuvastatin 0.5mg. The patient was allergic to Keflex, Bactrim and Codine. The patient did not have any other vaccine in four weeks. On 24Feb2021 20:15 , the patient experienced rash all over body and was very itchy. The patient received Claritin and Benadryl as treatment for the adverse events. The patient did not have covid prior to vaccination nor was tested positive since vaccination. The outcome of the events was recovering.  No follow-up attempts are possible. No further information is expected.
This spontaneous report as received from a pharmacy technician refers to a 4-year-old patient of unknown gender. The patient's concurrent conditions, medical history, drug reactions/allergies and concomitant medications were not reported. On 12-FEB-2018 the patient was vaccinated with improperly stored dose of VARIVAX (lot # N022979, expiry date: 23-AUG-2019) (dose, frequency and route were not reported) for prophylaxis. No adverse effect was reported. The VARIVAX temperature excursion occurred on 14-DEC-2017 and 30-DEC-2017. On 14-DEC-2017, the vaccine was exposed to the temperature of 16.9 degree Fahrenheit (F) for 30 minutes. On 30-DEC-2017, the vaccine was exposed to the temperature of 6 degree Fahrenheit (F) to 14 degree F for 30 minutes. It was reported that the event was because of data logger. No product quality complaint was involved. This is one of the several reports received from the same reporter.; Sender's Comments: US-009507513-1802USA001558:
Pt recvd vax & exp myalgia & paresthesia p/each dose; pt was seen by MD for sx; No further details were provided;
This spontaneous report as received from a Nurse Practitioner refers to an unknown number of patients were inadvertently vaccinated with GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB had been improperly store. No further information was provided. Additional information was received from Nurse practitioner, who reported that GARDASIL, RECOMBIVAX HB, VAQTA, and PEDVAXHIB went through multiple unsupported temperature excursions from 10/09/2013 to 10/17/2013. The Nurse practitioner reported GARDASIL (Lot# J003727, expiration date 11/07/2015) was administered to 2 unspecified patients on 10/10/13 (MARRS# 1310USA015162), 2 unspecified patients on 10/12/13 (MARRS # 1401USA000269), 1 unspecified patient on 10/14/13 (MARRS# 1410USA000273), 1 unspecified patient on 10/17/13 and 1 unspecified patient on 10/19/13 (MARRS# 1401USA000272). GARDASIL (Lot# J008423, expiration date 01/21/2016) was administered to 3 unspecified patients on 10/25/13(MARRS# 1401USA000268) and 1 unspecified patient on 10/26/13 (MARRS# 1401USA00027). VAQTA (Lot# J008090, expiration date 08/23/2015) was administered to 1 unspecified patient on 10/17/2013 (MARRS# 1401USA000279) and 1 unspecified patient on 0/25/2013(MARRS# 1401USA000278). RECOMBIVAX (Lot# H012250, expiration date 02/06/2015) was administered to 1 unspecified patient on 10/26/2013(MARRS# 1401USA000277). PEDVAXHIB (Lot# J005670, expiration 12/17/2015) was administered to 1 unspecified patient on 10/15/2013(MARRS# 1401USA000275), 1 unspecified patient on 10/25/2013 (MARRS# 1401USA000276) and 1 unspecified patient on 10/29/2013 (MARRS# 1401USA000280). No adverse effects reported. No further information was provided. Additional information has been requested.
I have swelling and pain in my underarm on the same side as my shot. My arm is still sore. But the swelling has not decreased . Started Saturday morning after my 2nd vaccine dose Friday night.; I have swelling and pain in my underarm on the same side as my shot. My arm is still sore. But the swelling has not decreased . Started Saturday morning after my 2nd vaccine dose Friday night.; This is a spontaneous report from a contactable healthcare professional (patient). A 31-year-old female patient received her second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number and expiry date were not provided) solution for injection, via an unspecified route of administration on left arm on 08Jan2021 19:00 at a single dose for Covid-19 immunization. Medical history included lymphoma, and red food coloring allergy. The patient received her first dose of BNT162B2 on 22Dec2020. The patient's concomitant medications were not reported. The patient reported she had swelling and pain in her underarm on the same side as her shot. Her arm was still sore, and the swelling has not decreased. It started Saturday morning (09Jan2021 at 6am) after her 2nd vaccine dose on Friday night. It was unknown if patient received any treatment. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Outcome of the event was not recovered.    Information about Lot/Batch number is requested.
Noticed neck mass 4/19. Had UltraSound, CT showing swollen lymph nodes and thyroid nodules. Had 2nd US, CT with contrast, and biopsies in hospital. Diagnosed with diffuse Large B Cell Lymphoma 5/9/2022. Had PET scan indicating Stage IV. Started R-CHOP chemotherapy 5/23/2022.   On 6/25/2022 had chest pain and in hospital diagnosed with pericarditis. On 6/30 tested positive for covid
injecting vaccine to patient less than 18; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (injecting vaccine to patient less than 18) in a 17-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (injecting vaccine to patient less than 18). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (injecting vaccine to patient less than 18) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (injecting vaccine to patient less than 18) to be not applicable.    No concomitant medications were provided  No treatment medications were provided
Dyspnoea at rest; Chest pain; Musculoskeletal chest pain; Dyspnoea exertional; Palpitations; Painful respiration; This spontaneous case was reported by a patient and describes the occurrence of DYSPNOEA AT REST (Dyspnoea at rest) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hypertension, Osteoporosis, Asthma, Glaucoma both eyes and Kearns-Sayre syndrome.   On 04-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-May-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In April 2023, the patient experienced DYSPNOEA AT REST (Dyspnoea at rest) (seriousness criterion medically significant), CHEST PAIN (Chest pain), MUSCULOSKELETAL CHEST PAIN (Musculoskeletal chest pain), DYSPNOEA EXERTIONAL (Dyspnoea exertional), PALPITATIONS (Palpitations) and PAINFUL RESPIRATION (Painful respiration). At the time of the report, DYSPNOEA AT REST (Dyspnoea at rest), CHEST PAIN (Chest pain), MUSCULOSKELETAL CHEST PAIN (Musculoskeletal chest pain), DYSPNOEA EXERTIONAL (Dyspnoea exertional), PALPITATIONS (Palpitations) and PAINFUL RESPIRATION (Painful respiration) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication use information was not provided by reporter.  Cardiac related signs and symptoms started on June 2023 and its resolved. Patient experienced symptoms like this before receiving the Moderna COVID-19 vaccine.  Treatment medication use information was not provided by reporter.  Company Comment: This is a spontaneous case concerning a 72 year-old, female patient with a history of asthma and hypertension, who experienced the serious (due to medically significant) unexpected, event of dyspnoea at rest, which occurred approximately 11 months after the fourth dose of mRNA-1273 vaccine. The outcome was reported as recovered. The mentioned medical history remains as a confounder. The company assessed the causality as not related to mRNA-1273 vaccine due to long latency and underlying medical history as risk factors. No further clinical information was available for medical review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2023-748712 (Patient Link).
Towards end of November a few weeks after my vaccine I did begin to have symptoms occur. I began to have bad pain in hip joint where it feels like my leg wants to disconnect from my hip along with lower back pain. Pain in my elbows as well. Reached out to PCP and they referred me to a rheumatologist  after not being able to find anything on X-rays. I have also had major brain fog where I forget things easily, and sometimes I will even have moments where it is hard for me to write out certain things correctly as I copy them. At the rheumatologist, I did get more testing done, and past blood work, inflammatory factors are running high and I was then diagnosed with  zero negative rheumatoid arthritis.  I am still currently having joint pain and the doctor did put me on medication to help with pain management. Some days they have worsened and other days when it is still around the baseline pain level.  I did contract COVID-19 January 13th 2022, overall fatigue, hard to breath, a lot of coughing, I never ran a fever. These symptoms lasted for about 10 days all together and the difficulty breathing had taken about 2-3 weeks.
I experienced AFib in late January 2023. I went to see my PCP on 02/09/2023 and he diagnosed me with AFib and have been wearing a heart monitor since 03/15/2023.
Low heart rate down to the 30s, chest pain, shortness of breath. chest pain has continued, left sided.
a wk p/vax fever 101-102, vomiting, cough, runny nose, rash & ear pain seen 22SEP97 lt ear inflamed & MD dx chickenpox rash;
had severe reaction that caused inflammation to the nerve; pain was unbearable; blockage of nerve, Pred for several weeks-pain meds;
Swelling, warmth, redness, and severe pain at injection site. Pain started at site almost immediately but continued to worsen throughout the day. The warmth, swelling, and redness began approx 5 hours later.   Also myalgias that began overnight and continue to persist.
The night that she received the vaccine (Thursday), she started being sick (nausea and diarrhea).  She was sick for three days with nausea, diarrhea, vomiting, excessive urination, fatigue. Today (Monday) she is finally starting to feel better. Her doctor and physical therapist were notified.
1/30/23  I woke up with a real bad sore throat. I thought I had a cold. I went to the clinic and was tested for COVID and it came back positive a few days later.  I lost my sense of taste and smell. I was very sleepy and exhausted. I went to the clinic and was prescribed Paxlovid. Within a day and a half of taking it, I felt much better. By 2/6/23 I felt better and the next day I got my sense of smell and taste back. Every once in a whle, I will still get something in my throat, like mucous. Sometimes something comes up and sometimes it does not. If I don?t take a cough drop, I will have a coughing fit.  I also feel like I am wheezing every once in a while.
painful at the site injection, fever, aches, and a cough - that is the concerning part, I have not read anything about a cough as a side affect. Fever (did not check it) lasted about 24 hours, broke the next night and slept fine. But two days later, I have a 99.9 temp, a minor cough (not persistent, and not bad, but occasional) and runny nose (it is also chilly outside). I am wondering if I have covid now or not, very concerned but it could simply be the reaction to the vaccine as well. I will call my Dr tomorrow and see what they say, and if the fever is gone again in the am.
This spontaneous report was received from a registered nurse via a company employee, referring to a patient of unknown age and gender. Patient's medical history and concurrent conditions were not reported. On an unknown date, the patient was vaccinated with hepatitis b vaccine (manufacturer unknown) (route, strength, dose, frequency and lot number were not reported). Concomitant medications were not reported. On an unknown date, the patient experienced diarrhea. At the time of reporting, the outcome of diarrhea and the causality with the vaccine were unknown. No product quality complaint was involved. Additional information has been requested.
Hives; Really bad fever; This spontaneous case was reported by an other health care professional and describes the occurrence of URTICARIA (Hives) and PYREXIA (Really bad fever) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced URTICARIA (Hives) and PYREXIA (Really bad fever). At the time of the report, URTICARIA (Hives) and PYREXIA (Really bad fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not provided. Treatment information was not provided.
Ten days following my first injection the injection site started itching, swelling, warm to touch, painful to touch, and redness
NO known adverse event. However, this individual was administered a Moderna Monovalent Primary 0.5 mL dose by a clinical support team member, when the individual should have received a Moderna Bivalent dose. This individual has already completed the Moderna Monovalent primary series (2 doses) and a 1/2 dose primary series booster (in April 2022).
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 73-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 18Sep2022 as dose 5 (booster), single (Lot number: gj5342) at the age of 73 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ELIQUIS, start date: Sep2021; TAMSULOSIN, start date: Jun2022; FINASTERIDE, start date: Jun2022; METOPROLOL, start date: Sep2021. Past drug history included: Clindamycin, reaction(s): "Known allergies: clindamycin". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19. Additional information: The patient received Paxlovid as treatment from 23Sep2022 to 27Sep2022.
Patient reports "disorientation".  He states that "it might not be the vaccine though because my doctor is adjusting my Levothyroxine dosage right now".  It lasted a couple of days.  Symptoms improved at the time of the completion of this report.
The patient is currently on maximum doses of epinephrine gtt, levophed gtt and vasopressin.  He is requiring 100% FiO2 and PEEP of 15  Chest xray reviewed with Dr., post CPR patient with worsening infiltrates bilaterally, possible bilateral pleural effusions, no pneumothorax.   He is being maximally supported at this time.  It has been discussed with the patients wife that  Further attempts at resuscitation would be futile.  We will continue life support measures and current treatment plan, but will not proceed with CPR if the patient has another cardiopulmonary arrest.  The patients wife requested that we not draw more labs at this time.
Extreme chills, Nausea, Frequent Vomiting, Fatigue, Aches